In Vivo Grade Recombinant Anti
-HIV CD4-Binding Site Human IgG1 Kappa Monoclonal Antibody (Clone N6)- ￥1600 - 15000
- Syd Labs
- 美国
- PA007171
- 2025年11月14日
- ELISA, Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
- Human
- HIV
企业认证
相关产品推荐更多 >
Polyclonal Antibody against Human RBP4
￥2200
In Vivo Grade Recombinant Anti-mouse GITR Rat IgG2a Lambda Monoclonal Antibody (Clone DTA-1)
￥1000In Vivo Grade Recombinant Human IgG1 Fc-L234A L235A P329G (LALAPG) Protein
￥2950Recombinant Anti-DNP Monoclonal Antibody, Mouse IgG2a (Clone DNP.m2)
￥1000Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody
￥1000
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
HIV CD4-Binding Site
- 亚型：
Human IgG1 Kappa
- 形态：
Liquid
- 保存条件：
Store at 2-8℃ and protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 克隆性：
Monoclonal Antibody
- 适应物种：
HIV
- 保质期：
如果保存在2 至 8°C，自收到之日起可保存1个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。
- 抗原来源：
HIV CD4-Binding Site
- 库存：
3 weeks
- 供应商：
青木生物技术（武汉）有限公司
- 宿主：
Human
- 应用范围：
ELISA, Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
- 浓度：
以实际发货为准
- 靶点：
HIV CD4-Binding Site
- 抗体英文名：
In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Human IgG1 Kappa Monoclonal Antibody (Clone N6)
- 抗体名：
In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Human IgG1 Kappa Monoclonal Antibody (Clone N6)
- 规格：
1mg/5mg/25mg
| 规格： | 1mg | 产品价格： | ￥1600.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥5000.0 |
| 规格： | 25mg | 产品价格： | ￥15000.0 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ANTIBODY BINDING TO PROTEIN A AND PROTEIN G
is available in which the albumin binding site has been deleted. Agarose beads coated with these proteins will bind antibodies and serve to immunoprecipitate antigens from solution. There are differences in the affinity of these proteins for antibodies
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
binding to the extracellular domains of the erbB- 2 protein have been developed (5 ,6 ). Several studies have demonstrated that a subset of these antibodies can elicit growth inhibition of erbB- 2 overexpressing cells both in vitro and in vivo
技术资料暂无技术资料 索取技术资料
